
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp has demonstrated a strong financial outlook, underscored by an increase in sales estimates for its product YUTREPIA (treprostinil) inhalation powder, now projected to reach peak sales of $1.7 billion to $2 billion due to stronger than expected market uptake. The company's successful initial launch has contributed to its operating profitability in the first full quarter of Yutrepia's introduction, with a significant sales figure of $18.8 million reported. Additionally, the growing patient conversion rate and improved six-minute walk distance (6MWD) results further enhance the company's prospects in addressing unmet patient needs within the pulmonary hypertension market.
Bears say
Liquidia Corp faces considerable legal risks that may threaten the exclusivity of YUTREPIA, its primary revenue source, which contributes to a negative outlook on the stock. The ongoing legal challenges concerning patent rights could adversely affect YUTREPIA's market operation, resulting in significant downside risk should the company not succeed in these cases. Additionally, a decline in R&D expenditures indicates a shift away from developmental initiatives, potentially undermining future growth and operational stability, further compounded by fears of achieving peak commercial revenue and securing necessary capital for ongoing operations.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares